



Ambu A/S - Capital increase in connection with exercise of warrants issued

In April 2012, Ambu A/S issued 507,600 warrants each carrying a right to subscribe for one B share of nominally DKK 2.5. These warrants were issued to 69 employees with a vesting period of 3 years and may therefore be exercised in the trading window which was opened 19 august 2016 in connection with Ambu's interim financial report for the third quarter 2015/16.

As a result, 1 employee has given instruction as to the exercise of 16,400 warrants to the agreed exercise price 39.5 in the current trading window and today, the Board of Directors of Ambu passed a resolution to carry out the capital increase relating to the warrants exercised.

By the capital increase, the share capital of Ambu will be increased by nominally DKK 41,000 from DKK 120,885,800 to DKK 120,926,800 by the issuing of 16,400 B shares. The share capital is now divided into 41,506,720 B shares of DKK 2.5 each and 6,864,000 A shares of DKK 2.5 each.

Following this exercise of warrants and in consideration of the employees having left the company, 53,200 remaining warrants relating to the 2012 program are now distributed between 5 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 2 September 2016 under the ISIN code of Ambu A/S' existing B shares (DK0010303619).

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

Ambu A/S
Baltorpbakken 13
DK-2750 Ballerup
Tel.: +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com

About Ambu

Since 1937, breakthrough ideas have driven Ambu's work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu bag and the legendary Blue Sensor® electrodes to our latest landmark solutions such as the aScope™ – the world's first single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medtech companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu has more than 2,350 employees in Europe, North America, Asia and the Pacific region. You can find more information about Ambu on our website: www.ambu.com.